Hormonal contraception is one of the contraceptive methods that act on the endocrine system. Several types of female hormones are used to prevent ovulation and avoid fertilization. Hormonal contraception can also cause changes in the uterus, making pregnancy less likely. Based on product, the market is segmented into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal ring and transdermal patches. These are safe and reliable forms of hormonal contraceptives to prevent pregnancy. Hormonal contraception has several potential benefits such as they can reduce the risk of uterine cancer, ovarian cancer, and colon cancer. They generally reduce menstrual (menstrual) blood flow. They can reduce painful periods and are very effective in preventing pregnancy.
Market Dynamics
Increased awareness about the benefits and use of contraceptives is a major factor driving the global hormonal contraceptives market. The ever-increasing global population, particularly in developing economies such as India, Brazil, China and others, is a growing source of concern around the world, necessitating government initiatives such as public awareness campaigns to eliminate or reduce the risk of unwanted pregnancies, abortion risks, and the threat of sexual disorders. For instance, according to data from the World Health Organization (WHO), 16 million girls between the ages of 15 and 19 give birth each year, which represents approximately 11% of all births in the world. To prevent these unintended births, the World Health Organization have launched global awareness programs such as "This is your life, this is your future". The London Family Planning Summit urged governments, international agencies and other private sectors to commit to improving the accessibility of voluntary family planning.
Key features of the study:
- This report provides in-depth analysis of the global hormonal contraceptives market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hormonal contraceptives market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
- Key companies covered as a part of this study include The Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell Ltd., Mayer Laboratories, Merck & Co., Inc., Church & Dwight, Co., Inc., Afaxys, Inc., Allergan plc., Agile Therapeutics, Apothecus Pharmaceutical Corporation., Novartis AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global hormonal contraceptives market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hormonal contraceptives market
Detailed Segmentation:
- Global Hormonal Contraceptives Market, By Product:
- Oral Contraceptive Pills
- Injectable Birth Control
- Emergency Contraceptive Pills
- Vaginal Ring
- Transdermal Patches
- Global Hormonal Contraceptives Market, By Hormone:
- Progestin Only Contraceptive
- Combined Hormonal Contraceptive
- Global Hormonal Contraceptives Market, By Age Group:
- 15–24 Years
- 25–34 Years
- 35–44 Years
- Above 44 Years
- Global Hormonal Contraceptives Market, By End User:
- Hospitals
- Homecare
- Gynecology Centers
- Clinics
- Ambulatory Surgical Centers
- Global Hormonal Contraceptives Market, By Region:
- North America
- By Product
- Oral Contraceptive Pills
- Injectable Birth Control
- Emergency Contraceptive Pills
- Vaginal Ring
- Transdermal Patches
- By Hormone
- Progestin Only Contraceptive
- Combined Hormonal Contraceptive
- By Age Group
- 15–24 Years
- 25–34 Years
- 35–44 Years
- Above 44 Years
- By End User
- Hospitals
- Homecare
- Gynecology Centers
- Clinics
- Ambulatory Surgical Centers
- By Country
- Latin America
- By Product
- Oral Contraceptive Pills
- Injectable Birth Control
- Emergency Contraceptive Pills
- Vaginal Ring
- Transdermal Patches
- By Hormone
- Progestin Only Contraceptive
- Combined Hormonal Contraceptive
- By Age Group
- 15–24 Years
- 25–34 Years
- 35–44 Years
- Above 44 Years
- By End User
- Hospitals
- Homecare
- Gynecology Centers
- Clinics
- Ambulatory Surgical Centers
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product
- Oral Contraceptive Pills
- Injectable Birth Control
- Emergency Contraceptive Pills
- Vaginal Ring
- Transdermal Patches
- By Hormone
- Progestin Only Contraceptive
- Combined Hormonal Contraceptive
- By Age Group
- 15–24 Years
- 25–34 Years
- 35–44 Years
- Above 44 Years
- By End User
- Hospitals
- Homecare
- Gynecology Centers
- Clinics
- Ambulatory Surgical Centers
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product
- Oral Contraceptive Pills
- Injectable Birth Control
- Emergency Contraceptive Pills
- Vaginal Ring
- Transdermal Patches
- By Hormone
- Progestin Only Contraceptive
- Combined Hormonal Contraceptive
- By Age Group
- 15–24 Years
- 25–34 Years
- 35–44 Years
- Above 44 Years
- By End User
- Hospitals
- Homecare
- Gynecology Centers
- Clinics
- Ambulatory Surgical Centers
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product
- Oral Contraceptive Pills
- Injectable Birth Control
- Emergency Contraceptive Pills
- Vaginal Ring
- Transdermal Patches
- By Hormone
- Progestin Only Contraceptive
- Combined Hormonal Contraceptive
- By Age Group
- 15–24 Years
- 25–34 Years
- 35–44 Years
- Above 44 Years
- By End User
- Hospitals
- Homecare
- Gynecology Centers
- Clinics
- Ambulatory Surgical Centers
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product
- Oral Contraceptive Pills
- Injectable Birth Control
- Emergency Contraceptive Pills
- Vaginal Ring
- Transdermal Patches
- By Hormone
- Progestin Only Contraceptive
- Combined Hormonal Contraceptive
- By Age Group
- 15–24 Years
- 25–34 Years
- 35–44 Years
- Above 44 Years
- By End User
- Hospitals
- Homecare
- Gynecology Centers
- Clinics
- Ambulatory Surgical Centers
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- The Female Health Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Limited
- Bayer AG
- Pfizer, Inc.
- Mylan N.V.
- Johnson & Johnson
- Ansell Ltd.
- Mayer Laboratories
- Merck & Co., Inc.
- Church & Dwight, Co., Inc.
- Afaxys, Inc.
- Allergan plc.
- Agile Therapeutics
- Apothecus Pharmaceutical Corporation.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
“*” marked represents similar segmentation in other categories in the respective section.
